Elke M. G. J. de Jong

Elke M. G. J. de Jong

Department Of Dermatology, Radboud University Medical Center, Rene Descartesdreef 1, 6525 Gl Nijmegen, The Netherlands Radboud University, Comeniuslaan 4, 6525 Hp Nijmegen, ...

Direct Impact

Concepts for which Elke M G J de has direct influence:

childhood psoriasis
older adults
drug survival
eosinophilic fasciitis
epidermal proliferation
sclerotic skin
localized scleroderma

External impact

Concepts related to the work of other authors for which Elke M G J de has influence:

genital psoriasis
eosinophilic fasciitis
psoriatic arthritis
atopic dermatitis
french prospective
anti-tnf-α therapy
older adults

Prominent publications by Elke M. G. J. de Jong

KOL-Index: 112 Background: Previously identified risk factors for psoriatic arthritis (PsA); nail dystrophy and scalp lesions are highly prevalent in patients with moderate-to-severe psoriasis. Therefore, these variables may not be useful as predictors for PsA in this population. Objective: We assessed the predictive value of demographic and clinical characteristics for development of PsA in a cohort of ...
Known for
Psoriasis Biologics | Characteristics Developed | Concomitant New-Onset Psoriatic Arthritis | New-Onset Psa
KOL-Index: 98 Morphea, also known as localized scleroderma, encompasses a group of idiopathic sclerotic skin diseases. The spectrum ranges from relatively mild phenotypes, which generally cause few problems besides local discomfort and visible disfigurement, to subtypes with severe complications such as joint contractures and limb length discrepancies. Eosinophilic fasciitis (EF, Shulman syndrome) is ...
KOL-Index: 88 BACKGROUND: Patients with inflammatory bowel disease (IBD) are at increased risk to develop malignant melanoma and this risk may increase with use of anti-tumor necrosis factor (TNF) therapy. Impaired survival of immunosuppressed melanoma patients is reported in transplant and rheumatology patients. This study aims to (1) identify risk factors for melanoma development in patients with IBD, ...
Known for
Immunosuppressive Anti-Tnf Therapy | Ibd Anti | 2 Case-Control | Lower N-Stage
KOL-Index: 69 Twenty to thirty percent of psoriasis (Pso) patients will develop psoriatic arthritis (PsA). Detection of Pso patients that are (at risk for) developing PsA is essential to prevent structural damage. We conducted a systematic search of five bibliographic databases, up to May 2020. We searched for studies assessing markers (clinical, laboratory, genetic) associated with the development or ...
Known for
119 | Markers Laboratory | Structural Damage | Cxcl10
KOL-Index: 63 Importance: Few studies have examined watchful waiting (WW) in patients with basal cell carcinoma (BCC), although this approach might be suitable in patients who might not live long enough to benefit from treatment. Objective: To evaluate reasons for WW and to document the natural course of BCC in patients who chose WW and reasons to initiate later treatment. Design, Setting, and ...
Known for
Waiting Chosen | Component Prediction | Superficial Bccs | Carcinoma Bcc
KOL-Index: 54 BACKGROUND: Evidence-based recommendations for therapeutic decision making in childhood psoriasis are lacking. OBJECTIVES: We sought to systematically review all available literature concerning treatment efficacy and safety in childhood psoriasis and to propose a recommendation for topical and systemic treatment of childhood psoriasis. METHODS: Databases searched were PubMed, EMBASE, and the ...
KOL-Index: 48 BACKGROUND: Biologics are indicated for treating moderate-to-severe psoriasis. As the number of biologics registered for the treatment of psoriasis increases, so does the need for biomarkers to guide personalized therapeutic decisions. Genetic variants might serve as predictors for treatment response, a field of research known as pharmacogenetics. OBJECTIVES: To assess which genetic variants ...
Known for
Larger Cohorts | Pharmacogenetics | Large-Scale Hypothesis-Free Searches | Moderate-To-Severe Psoriasis
KOL-Index: 46 BACKGROUND: There is limited information on systemic and biological treatment optimization and transitioning in routine clinical practice. OBJECTIVE: To provide practical guidance on treatment optimization and transitioning for moderate-to-severe plaque psoriasis. METHODS: Dermatologists from 33 countries contributed to the Transitioning Therapies programme. Fourteen questions were ...
Known for
Globe | Therapy Biological | 7-9 Range | Drug Exposure
KOL-Index: 41 IntroductionBiologics serve as a cornerstone in psoriasis treatment, with low disease activity or sometimes even clinical remission as a realistic treatment outcome. So far, it is unclear whether biologics should be tapered when this target is achieved. Dose tapering could offer potential benefits by decreasing side effects, the burden of repetitive injections and costs of biological ...
Known for
Remission Biologic | Response Relapse | Criteria Tapering | Psoriasis Scoping
KOL-Index: 39 BACKGROUND: Most psoriasis patients suffering from mild to moderate disease are treated with first-line topical treatments, including corticosteroids, vitamin D analogues, topical retinoids and calcineurin inhibitors. Although evidence-based guidelines on combinations are lacking, the majority of patients will be treated with combinations of these popular topicals at some point during their ...
Known for
First-Line Treatments | Evidence-Based Guidelines | Potent Superpotent Corticosteroids | Once-Daily

Department of Dermatology, Radboud University Medical Center, Rene Descartesdreef 1, 6525 GL Nijmegen, The Netherlands Radboud University, Comeniuslaan 4, 6525 HP Nijmegen, The Netherlands

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172